Cardamonin Modulates Neuropathic Pain through the Possible Involvement of Serotonergic 5-HT1A Receptor Pathway in CCI-Induced Neuropathic Pain Mice Model

被引:22
作者
Kaswan, Nur Khalisah [1 ]
Mohammed Izham, Noor Aishah Binti [1 ]
Tengku Mohamad, Tengku Azam Shah [1 ]
Sulaiman, Mohd Roslan [1 ]
Perimal, Enoch Kumar [1 ,2 ]
机构
[1] Univ Putra Malaysia UPM, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang 43400, Selangor, Malaysia
[2] Univ Adelaide, Ctr Excellence Nanoscale BioPhoton, Australian Res Council, Adelaide, SA 5005, Australia
关键词
cardamonin; neuropathic pain; serotonin; 5-HT1A; PCPA; chronic constriction injury; CCI; spinal cord and brainstem; SUBTYPE MESSENGER-RNAS; DORSAL-ROOT GANGLION; RAT SPINAL-CORD; SYNAPTIC-TRANSMISSION; PATHOPHYSIOLOGICAL MECHANISMS; DESCENDING FACILITATION; REGIONAL-DISTRIBUTION; MOUSE MODEL; ACTIVATION; HYPERSENSITIVITY;
D O I
10.3390/molecules26123677
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardamonin, a naturally occurring chalcone isolated from Alpinia species has shown to possess strong anti-inflammatory and anti-nociceptive activities. Previous studies have demonstrated that cardamonin exerts antihyperalgesic and antiallodynic properties in chronic constriction injury (CCI)-induced neuropathic pain animal model. However, the mechanisms underlying cardamonin's effect have yet to be fully understood. The present study aims to investigate the involvement of the serotonergic system in cardamonin induced antihyperalgesic and antiallodynic effects in CCI-induced neuropathic pain mice model. The neuropathic pain symptoms in the CCI mice model were assessed using Hargreaves Plantar test and von-Frey filament test on day 14 post-surgery. Central depletion of serotonin along the descending serotonergic pathway was done using rho-chlorophenylalanine (PCPA, 100 mg/kg, i.p.), an inhibitor of serotonin synthesis for four consecutive days before cardamonin treatment, and was found to reverse the antihyperalgesic and antiallodynic effect produced by cardamonin. Pretreatment of the mice with several 5-HT receptor subtypes antagonists: methiothepin (5-HT1/6/7(7) receptor antagonist, 0.1 mg/kg), WAY 100635 (5-HT1A receptor antagonist, 1 mg/kg), isamoltane (5-HT1B receptor antagonist, 2.5 mg/kg), ketanserin (5-HT2A receptor antagonist, 0.3 mg/kg), and ondansetron (5-HT3 receptor antagonist, 0.5 mg/kg) were shown to abolish the effect of cardamonin induced antihyperalgesic and antiallodynic effects. Further evaluation of the 5-HT1A receptor subtype protein expressions reveals that cardamonin significantly upregulated its expression in the brainstem and spinal cord. Our results suggest that the serotonergic pathway is essential for cardamonin to exert its antineuropathic effect in CCI mice through the involvement of the 5-HT1A receptor subtype in the central nervous system.
引用
收藏
页数:18
相关论文
共 111 条
[1]  
Agosti Reto M., 2007, CNS & Neurological Disorders-Drug Targets, V6, P235
[2]   Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood [J].
Ahmad, Syahida ;
Israf, Daud A. ;
Lajis, Nordin Hj. ;
Shaari, Khozirah ;
Mohamed, Habsah ;
Wahab, Afiza A. ;
Ariffin, Khaizurin T. ;
Hoo, Wei Yee ;
Aziz, Nasaruddin A. ;
Kadir, Arifah A. ;
Sulaiman, Mohamad R. ;
Somchit, Muhammad N. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 538 (1-3) :188-194
[3]   SUBTYPE-SPECIFIC CHANGES IN 5-HT RECEPTOR-MEDIATED MODULATION OF C FIBRE-EVOKED SPINAL FIELD POTENTIALS ARE TRIGGERED BY PERIPHERAL NERVE INJURY [J].
Aira, Z. ;
Buesa, I. ;
Salgueiro, M. ;
Bilbao, J. ;
Aguilera, L. ;
Zimmermann, M. ;
Azkue, J. J. .
NEUROSCIENCE, 2010, 168 (03) :831-841
[4]   Preclinical and Early Clinical Investigations Related to Monoaminergic Pain Modulation [J].
Bannister, Kirsty ;
Bee, Lucy A. ;
Dickenson, Anthony H. .
NEUROTHERAPEUTICS, 2009, 6 (04) :703-712
[5]   The complex role of serotonin and 5-HT receptors in chronic pain [J].
Bardin, Laurent .
BEHAVIOURAL PHARMACOLOGY, 2011, 22 (5-6) :390-404
[6]   International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function [J].
Barnes, Nicholas M. ;
Ahern, Gerard P. ;
Becamel, Carine ;
Bockaert, Joel ;
Camilleri, Michael ;
Chaumont-Dubel, Severine ;
Claeysen, Sylvie ;
Cunningham, Kathryn A. ;
Fone, Kevin C. ;
Gershon, Michael ;
Di Giovanni, Giuseppe ;
Goodfellow, Nathalie M. ;
Halberstadt, Adam L. ;
Hartley, Rachel M. ;
Hassaine, Gherici ;
Herrick-Davis, Katharine ;
Hovius, Ruud ;
Lacivita, Enza ;
Lambe, Evelyn K. ;
Leopoldo, Marcello ;
Levy, Finn Olav ;
Lummis, Sarah C. R. ;
Marin, Philippe ;
Maroteaux, Luc ;
McCreary, Andrew C. ;
Nelson, David L. ;
Neumaier, John F. ;
Newman-Tancredi, Adrian ;
Nury, Hugues ;
Roberts, Alexander ;
Roth, Bryan L. ;
Roumier, Anne ;
Sanger, Gareth J. ;
Teitler, Milt ;
Sharp, Trevor ;
Villalon, Carlos M. ;
Vogel, Horst ;
Watts, Stephanie W. ;
Hoyer, Daniel .
PHARMACOLOGICAL REVIEWS, 2021, 73 (01) :310-520
[7]   Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment [J].
Baron, Ralf ;
Binder, Andreas ;
Wasner, Gunnar .
LANCET NEUROLOGY, 2010, 9 (08) :807-819
[8]   Activation of 5-HT1B/1D receptor in the periaqueductal gray inhibits nociception [J].
Bartsch, T ;
Knight, YE ;
Goadsby, PJ .
ANNALS OF NEUROLOGY, 2004, 56 (03) :371-381
[9]   Descending monoaminergic pain modulation - Bidirectional control and clinical relevance [J].
Benarroch, Eduardo E. .
NEUROLOGY, 2008, 71 (03) :217-221
[10]   A PERIPHERAL MONONEUROPATHY IN RAT THAT PRODUCES DISORDERS OF PAIN SENSATION LIKE THOSE SEEN IN MAN [J].
BENNETT, GJ ;
XIE, YK .
PAIN, 1988, 33 (01) :87-107